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Abstract 
 
Hop/STI1 (Hsp-organizing protein/stress-induced-phosphoprotein 1) is a molecular co-
chaperone, which coordinates Hsp70 and Hsp90 activity during client protein folding 
through interactions with its TPR1 and TPR2A domains. Hsp90 substrates include a 
diverse set of proteins, many of which have been implicated in tumorogenesis. Over-
expression of Hsp90 in cancer cells stabilizes mutant oncoproteins promoting cancer cell 
survival. Disruption of Hsp90 and its co-chaperone machinery has become a promising 
strategy for the treatment of cancer. STI1 has also been described as a neurotrophic 
signaling molecule through its interactions with the prion protein (PrPC). Here, we report 
the 1H, 13C and 15N backbone assignments of the TPR1 and TPR2A domains of mouse 
STI1, which interact with Hsp70 and Hsp90, respectively. 1H-15N HSQC spectra of 
TPR2A domain in the presence of a peptide encoding the C-terminal Hsp90 binding site 
revealed significant chemical shift changes indicating complex formation. These results 
will facilitate the screening of potential molecules that inhibit STI1 complex formation 
with Hsp70 and/or Hsp90 for the treatment of cancer and detailed structural studies of the 
STI1-PrPC complex.   
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Biological context 
 
Heat-shock protein (Hsp)70 and Hsp90 are chaperones which mediate folding of 
key cellular client proteins involved in processes such as proliferation, differentiation and 
apoptosis (Taipale et al. 2010; Young et al. 2004). Hsp90 targets numerous proteins 
implicated in tumor growth and survival including steroid hormone receptors and proto-
oncogenic kinases such as Akt (Sato et al. 2000), Raf-1 (Stancato et al. 1993) and 
Her2/neu (Xu et al. 2001). Hsp90 over-expression correlates with tumor invasiveness and 
poor prognosis, thus pharmacological inhibition of the chaperone response has become an 
alluring target for therapeutic intervention in multiple cancer types (Trepel et al. 2010). 
Client maturation is facilitated by a number of co-chaperone proteins that regulate 
Hsp70 and Hsp90 activity. Hop/STI1 (Hsp-organizing protein/stress-induced-
phosphoprotein 1) is a key scaffold protein, which mediates client transfer from Hsp70 to 
Hsp90 in the later stages of client maturation (Smith et al. 1993; Chen and Smith 1998). 
Initially, client proteins complex with Hsp40 and Hsp70 (Hernandez et al. 2002; Pratt and 
Toft 2003). Then Hop/STI1 promotes client transfer from Hsp70 to Hsp90 by 
simultaneously binding the two chaperones through distinct tetracopeptide repeat (TPR) 
domains  (Scheufler et al. 2000).  
Hop/STI1 encodes three TPR domains, TPR1, TPR2A and TPR2B and two 
aspartate-proline motif regions (DP1 and DP2) (Odunuga et al. 2003). TPR domains are 
composed of multiple degenerate 34 amino acid repeats forming anti-parallel helix-turn-
helix motifs. These serve as protein-protein interaction modules in multi-protein 
complexes (Cortajarena and Regan 2006). TPR1 and TPR2A preferentially bind the 
conserved C-terminal residue ‘EEVD’ motifs of Hsp70 and Hsp90, respectively. X-ray 
crystallographic data of human TPR1 and TPR2A domain in complex with Hsp70 and 
Hsp90 C-terminal peptides indicate specificity is determined by hydrophobic contacts 
directly N-terminal of the ‘EEVD’ motif (Scheufler et al. 2000).   
Studies have demonstrated that STI1 promotes proliferation and migration in 
glioblastoma and pancreatic cancer cell lines (Fonseca et al. 2012; Walsh et al. 2011). 
Down-regulation of STI1 by RNAi resulted in decreased pancreatic cell line invasiveness 
and down-regulation of numerous oncogenic Hsp90 client proteins (Walsh et al. 2011). 
Inhibition of Hsp90 interaction with the TPR2A domain of STI1 using a novel hybrid 
TPR peptide has demonstrated selective cancer-cell cytotoxicity (Horibe et al. 2011). 
Secreted STI1 also functions as a cell-signaling molecule promoting neuritogenesis and 
neuroprotection to hippocampal neurons through its interaction with the cellular prion 
protein (PrPC) (Zanata et al. 2002; Lopes et al. 2005). The PrPC binding site of STI1 has 
been localized to the TPR2A domain of STI1. The neurotrophic signaling induced by 
PrPC-STI1 binding may have a role in the pathology of neurodegenerative diseases. 
Backbone resonance assignment of the TPR1 and TPR2A domains will facilitate 
screening of further selective inhibitors of Hsp complex formation that may prove 
effective in cancer treatment and for future studies involving the STI1-PrPC signaling 
complex.  
 
 
Methods and experiments 
 
Plasmid generations 
 
The expression vector pTrcHis containing mouse STI1 cDNA (GenBank# NM_016737) 
was graciously provided by Dr. Vilma Martins (A.C. Camargo Hospital, Sao Paulo, 
Brazil). Sequence encoding the TPR1 domain, residues 2-118, were amplified by PCR 
using the two primers: 
5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTCTGAAAACCTGTATTTTCAGG 
GAGAGCAGGTGAATGAGCTAAAGG-3’ and  
5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACCTGGCCTCCATGTTCT 
G-3’.  
TPR2A domain, residues 217-352, were amplified by two successive rounds of PCR 
using primers 5’-GAAAACCTGTATTTTCAGGGAGATCTTCCAGAGAATAA-3’ and 
5’-AAGAAAGCTGGGTCTCACAAGCGCTCCTG-3’ followed by amplification using 
5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTCTGAAAACCTGTATTTTC-3’ 
and 5’-GGGGACCACTTTGTACAAGAAAGCTGGG-3’. The resultant cDNA was 
cloned into separate pDEST17 (Invitrogen) expression vectors with an additional tobacco 
etch virus (TEV) cleavage recognition site ‘ENLYFQG’ between the 6xHis tag and the 
insert. 
 
Sample preparation  
 
The expression vectors containing mouse TPR1 and TPR2A were transformed in E. coli 
BL21 (DE3) pLysS. Uniformly 15N, 13C- labeled protein was over-expressed by growing 
E. coli in 1 L M9 media supplemented with 1 g of NH4Cl and 3 g of 13C-glucose at 37°C 
to an OD600 of 0.9, at which point protein over-expression was induced with 1 mM IPTG. 
Cultures grew for 6 hours at 37 °C and centrifuged pellets were frozen. N-terminally His-
tagged fusion proteins were purified by affinity chromatography using Ni SepharoseTM 6 
Fast Flow beads (Amersham Biosciences). The N-terminal His-tag was removed by 
incubation with His-tagged TEV protease overnight at 22 °C. TEV protease was removed 
by an additional affinity chromatography step using Ni SepharoseTM 6 Fast Flow beads 
(Amersham Biosciences). Proteins were dialyzed into 50 mM sodium phosphate buffer, 
50 mM NaCl, 1mM DTT at pH 7 and subsequently concentrated to ~ 500 µM. NMR 
samples contained 10 % D2O and 100 µM 2,2-dimethyl-2-sila-pentane-5-sulfonic acid 
(DSS) for 1H and 13C chemical shift referencing.  
 
NMR spectroscopy 
 
NMR experiments for backbone resonance assignments of TPR1 and TPR2A were 
conducted at 25°C on a Varian INOVA 600 MHz spectrometer equipped with either a 
cryogenic probe or a regular triple resonance probe (UWO Biomolecular NMR Facility). 
Sequential assignments were obtained for the TPR1 domain using the following 
experiments: HNCACB and CBCA(CO)NH and C(CO)NH spectra. The TPR2A domain 
was assigned using HNCACB and CBCA(CO)NH experiments. All spectra were 
processed using NMRPipe (Delaglio et al. 1995) and analyzed using CARA (Keller 
2004). 
 
Ligand Binding experiment 
 
Binding of the TPR2A domain to the peptide encoding the C-terminal Hsp90 residues 
(Ac-MEEVD-NH2 ordered from GenScript Inc. USA) was confirmed by 1H-15N HSQC 
spectra collected in the presence and absence of equimolar concentrations of Hsp90 
peptide (~250 µM). Experiments were collected on a Varian INOVA 600 MHz 
spectrometer equipped with a cryogenic probe (UWO Biomolecular NMR Facility). 
 
Assignments and data deposition 
 
Backbone resonance assignments for 1HN, 15N, 13Cα and 13Cβ were obtained for the 
TPR1 and TPR2A domains of STI1. For the TPR1 domain, 97% of the 1HN and 15N 
resonances of non-proline residues, 94% 13Cα and 87% 13Cβ of all residues were 
assigned (Fig. 1). For the TPR2A domain, 99% of 1HN and 15N resonances of non-proline 
residues, 95% 13Cα and 96% 13Cβ of all residues were assigned (Fig. 2). Chemical shift 
assignments have been deposited in the BioMagResBank (http://www.bmrb.wisc.edu), 
under accession numbers 18691 and 18689 for the TPR1 and TPR2A domains, 
respectively. 
 Crystal structures of TPR1 and TPR2A in complex with C-terminal peptides of 
Hsp70 and Hsp90 indicate each domain to be composed of seven α-helices arranged in 
anti-parallel helix-turn-helix motifs (Scheufler et al. 2000) (PDB: 1ELW for TPR1 and 
PDB:  1ELR for TPR2A). Secondary structure propensity (SSP) scores (Marsh et al. 
2006) using 13C α/β chemical shifts indicate no β-strand propensity in TPR1 or TPR2A 
domains and agree with the secondary structure diagram (Laskowski 2009) generated 
from the TPR1 and TPR2A crystal structures (Fig. 3) (Scheufler et al. 2000). 
 1H-15N HSQC of the TPR2A domain collected in the absence and presence of 
equimolar concentrations of Hsp90 C-terminal peptide produced large chemical shift 
changes indicative of binding (Fig. 4a). The magnitude of chemical shift perturbations for 
traceable residues was calculated from the combined chemical shift changes in 1H and 
15N dimensions (Δω = |0.2 * Δ15N| + |Δ1HN|) in ppm. Residues demonstrating the largest 
combined chemical shift changes (> 0.1 ppm) clustered to the binding interface of the 
TPR2A-Hsp90 C-terminal peptide complex (Fig. 4b) (Scheufler et al. 2000) further 
confirming the assignment.  
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Figure Legends 
 
Fig. 1 a 1H-15N HSQC spectrum and backbone resonance assignment of 15N/13C labeled 
TPR1 domain of STI1. Spectra were generated using Sparky (Goddard and Kneller). b 
Amino acid sequence of TPR1 domain with unassigned residues colored red. The N-
terminal glycine is a non-native residue from the TEV protease recognition site.  
 
Fig. 2 a 1H-15N HSQC spectrum and backbone resonance assignment of 15N/13C labeled 
TPR2A domain of STI1. Spectra were generated using Sparky (Goddard and Kneller). b 
Amino acid sequence of TPR2A domain with unassigned residues colored red. The N-
terminal glycine is a non-native residue from the TEV protease recognition site. 
 
Fig. 3 Secondary structure propensity (SSP) scores and DSSP analysis of a the TPR1 and 
b TPR2A domains of STI1. 13C α/β chemical shifts were used to calculate SSP scores for 
each domain (Marsh et al. 2006). Crystal structures of TPR1 in complex with Hsp70 C-
terminal peptide (PDB: 1ELW) and TPR2A in complex with C-terminal Hsp90 peptide 
(PDB: 1ELR) (Scheufler et al. 2000) were used to generate the secondary structure 
diagrams of each domain (Laskowski 2009). 
 
Fig. 4 a Overlay of 1H-15N HSQC spectra of TPR2A in the absence (black) and presence 
(red) of equimolar concentrations of Hsp90 C-terminal peptide. b Crystal structure of 
TPR2A in complex with Hsp90 peptide (PDB: 1ELR; Scheufler et al. 2000) with 
traceable chemical shift changes upon addition of Hsp90 peptide colored based on the 
magnitude of the combined chemical shift changes in 1H and 15N dimensions. 
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